TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Klotho Neurosciences ( (KLTO) ) has issued an announcement.
On June 16, 2025, Klotho Neurosciences announced that it raised over $11 million through the exercise of existing warrants, which allowed the company to exceed Nasdaq’s stockholders’ equity requirements and retire all outstanding debt, resulting in a debt-free balance sheet. This financial maneuver positions Klotho Neurosciences favorably for continued Nasdaq listing and potentially strengthens its market position in the biogenetics industry.
More about Klotho Neurosciences
Klotho Neurosciences, Inc. is a U.S.-based biogenetics company focused on developing innovative cell and gene therapies for neurodegenerative and age-related disorders such as ALS, Alzheimer’s, and Parkinson’s disease. The company utilizes a patented form of the ‘anti-aging’ human Klotho gene and its novel promoter and delivery systems, with a portfolio that includes DNA and RNA therapeutics and genomics-based diagnostic assays.
Average Trading Volume: 37,526,340
Technical Sentiment Signal: Buy
Current Market Cap: $51.99M
See more data about KLTO stock on TipRanks’ Stock Analysis page.